# Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

> **NCT02044822** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 102 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02044822
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-06
- **Primary completion:** 2016-04-27
- **Final completion:** 2016-05-17
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044822, "Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02044822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*